丙戊酸镁防治偏头痛的疗效观察
Effect of magnesium valprote in the treatment of migraine
-
摘要: 目的:探讨丙戊酸镁治疗偏头痛的有效性及安全性。方法:81例偏头痛患者,其中因失访脱落6例,按照就诊顺序编号,奇数者为氟桂利嗪组(37例,给予氟桂利嗪治疗),偶数者为丙戊酸镁组(38例,给予丙戊酸镁缓释片治疗)。观察2组患者治疗前及治疗3个月后的头痛发作频率及头痛严重程度。结果:治疗后氟桂利嗪组和丙戊酸镁组头痛发作频率均较治疗前明显降低(P<0.01),但2组差异无统计学意义(P>0.05);治疗后氟桂利嗪组和丙戊酸镁组头痛严重程度评分均较治疗前显著降低(P<0.01),且2组差异有统计学意义(P<0.05)。2组患者药物的不良反应率分别为18.92%和23.68%,差异无统计学意义(P>0.05)。结论:丙戊酸镁用于防治偏头痛安全有效。Abstract: Objective:To explore the effects and safety of magnesium valproate in the treatment of migraine.Methods:Eighty-one patients with migraine(including miss follow-up 6 cases) were randomly divided into the flunarizine group(37 cases treated with flunarizine) and magnesium valprote group(38 cases treated with magnesium).Compared with before treatment, the frequency of headache attack and severity of headache in two groups after 3 months of treatment were analyzed.Results:Compared with before treatment, the frequency of headache attack in two groups decreased significantly(P<0.01), and the difference of which between two groups was not statistically significant after treatment(P>0.05).Compared with before treatment, the scores of headache severity in two groups decreased significantly(P<0.01), and the difference of which between two groups was statistically significant after treatment(P>0.05).The incidences of adverse reactions in flunarizine group and magnesium valprote group were 18.92% and 23.68%, respectively, the difference of which was not statistically significant(P>0.05).Conclusions:Magnesium valproate treating migraine is secure and effective.
-
Key words:
- migraine /
- magnesium valproate /
- flunarizine
-
[1] ZAMEEL CADER M. The molecular pathogenesis of migraine:new developments and opportunities[J]. Hum Mol Genet,2013, 22(R1):R39. [2] 李舜伟,李焰生,刘若卓,等. 中国偏头痛诊断冶疔指南[J]. 中国疼痛医学杂志,2011,17(2):65. [3] ABU-ARAFEH I. Flunarizine for the prevention of migraine-a new look at an old drug[J]. Dev Med Child Neurol,2012,54(3):204. [4] SHAHIEN R,SALEH SA,BOWIRRAT A. Intravenous sodium valproate aborts migraine headaches rapidly[J]. Acta Neurol Scand,2011,123(4):257. [5] ALI Ⅱ,HERIAL NA,ORRIS M,et al. Migraine prophylaxis with topiramate and bone health in women[J]. Headache,2011,51(4):613. [6] LINDE M,MULLENERS WM,CHRONICLE EP,et al. Valproate(valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults[J]. Cochrane Database Syst Rev,2013,6(6):CD 010611. [7] MAUSKOP A,VARUGHESE J. Why all migraine patients should be treated with magnesium[J]. J Neural Transm,2012,119(5):575. [8] SILBERSTEIN SD,WINNER PK,CHMIEL JJ. Migraine preventive medication reduces resourceutiliz ation[J]. Headache,2003, 43(3):171. [9] GRACIA-NAYA M, RíOS C, GARCía-GOMARA MJ, et al. A comparative study of the effectiveness of topiramate and flunarizine in independent series of chronic migraine patients without medication abuse[J]. Rev Neurol,2013,57(8):347. [10] BOSTANI A,RAJABI A,MORADIAN N,et al. The effects of cinnarizine versus sodium valproate in migraine prophylaxis[J]. Int J Neurosci,2013,123(7):487. [11] TAJMIRRIAHI M,SOHELIPOUR M,BASIRI K,et al. The effects of sodium valproate with fish oil supplementation or alone in migraine prevention:a randomized single-blind clinical trial[J]. Iran J Neurol,2012,11(1):21. [12] RAPOPORT AM,BIGAL ME. Preventive migraine therapy:what is new[J]. Neurol Sci,2004,25(3):s177. [13] MULL ENERS WM,CH RONICLE EP,VREDEVELD JW,et al. Visual cortex excitability in migraine before and after valproat eprophylax is:a pilot study using TMS[J]. Eur J Neurol,2002,9(1):35. [14] GONULLU H,GONULLU E,KARADAS S,et al. The levels of trace elements and heavy metals in patients with acute migraine headache[J]. J Pak Med Assoc,2015,65(7):694. -

计量
- 文章访问数: 2852
- HTML全文浏览量: 552
- PDF下载量: 122
- 被引次数: 0